Interestingly, the parkin substrate AIMP2 reported a 7-fold upregulation in PD when compared to controls (Fig. 2B), although such levels are relatively maintained low with little variation in controls, as opposed to other target genes (Fig. 2). This evidence concerns the gene PRKN and Parkinson disease.